StreetInsider.com News Articles

Sensorion Reports 2025 Half-Year Results, Provides Corporate Update and Announces Availability of Half-Year Report

Wed, 17 Sep 2025 01:30:00 -0400

Achieved expedited enrollment completion of first two Cohorts in Phase 1/2 Audiogene clinical trial evaluating SENS-501, the Company’s gene therapy candidate being developed to treat a specific form of congenital deafness linked to mutations in the OTOF (otoferlin) gene
- Positive initial safety profile reported in all six patients treated so far
- Data from Cohort 1, at the minimally effective dose, demonstrate early signs of hearing improvement in Patient 3, using a range of standard hearing tests
- Data from Cohort 2, at a higher dose, are currently being gathered; Data Monitoring Committee expected by the end of H2 2025
GJB2-GT on track for

Sensorion Reports 2025 Half-Year Results, Provides Corporate Update and Announces Availability of Half-Year Report

Wed, 17 Sep 2025 01:30:00 -0400

Achieved expedited enrollment completion of first two Cohorts in Phase 1/2 Audiogene clinical trial evaluating SENS-501, the Company’s gene therapy candidate being developed to treat a specific form of congenital deafness linked to mutations in the OTOF (otoferlin) gene

Positive initial safety profile reported in all six patients treated so far

Data from Cohort 1, at the minimally effective dose, demonstrate early signs of hearing improvement in Patient 3, using a range of standard hearing tests

Data from Cohort 2, at a higher dose, are currently being gathered; Data Monitoring Committee expected by the end of H2 2025

GJB2-GT on track for

Sensorion Reports 2025 Half-Year Results, Provides Corporate Update and Announces Availability of Half-Year Report

Wed, 17 Sep 2025 01:30:00 -0400

Achieved expedited enrollment completion of first two Cohorts in Phase 1/2 Audiogene clinical trial evaluating SENS-501, the Company’s gene therapy candidate being developed to treat a specific form of congenital deafness linked to mutations in the OTOF (otoferlin) gene

Positive initial safety profile reported in all six patients treated so far

Data from Cohort 1, at the minimally effective dose, demonstrate early signs of hearing improvement in Patient 3, using a range of standard hearing tests

Data from Cohort 2, at a higher dose, are currently being gathered; Data Monitoring Committee expected by the end of H2 2025

GJB2-GT on track for

Sensorion Reports 2025 Half-Year Results, Provides Corporate Update and Announces Availability of Half-Year Report

Wed, 17 Sep 2025 01:30:00 -0400

Achieved expedited enrollment completion of first two Cohorts in Phase 1/2 Audiogene clinical trial evaluating SENS-501, the Company’s gene therapy candidate being developed to treat a specific form of congenital deafness linked to mutations in the OTOF (otoferlin) gene

Positive initial safety profile reported in all six patients treated so far

Data from Cohort 1, at the minimally effective dose, demonstrate early signs of hearing improvement in Patient 3, using a range of standard hearing tests

Data from Cohort 2, at a higher dose, are currently being gathered; Data Monitoring Committee expected by the end of H2 2025

GJB2-GT on track for

Sensorion Reports 2025 Half-Year Results, Provides Corporate Update and Announces Availability of Half-Year Report

Wed, 17 Sep 2025 01:30:00 -0400

Achieved expedited enrollment completion of first two Cohorts in Phase 1/2 Audiogene clinical trial evaluating SENS-501, the Company’s gene therapy candidate being developed to treat a specific form of congenital deafness linked to mutations in the OTOF (otoferlin) gene

Positive initial safety profile reported in all six patients treated so far

Data from Cohort 1, at the minimally effective dose, demonstrate early signs of hearing improvement in Patient 3, using a range of standard hearing tests

Data from Cohort 2, at a higher dose, are currently being gathered; Data Monitoring Committee expected by the end of H2 2025

GJB2-GT on track for

Sensorion Reports 2025 Half-Year Results, Provides Corporate Update and Announces Availability of Half-Year Report

Wed, 17 Sep 2025 01:30:00 -0400

Achieved expedited enrollment completion of first two Cohorts in Phase 1/2 Audiogene clinical trial evaluating SENS-501, the Company’s gene therapy candidate being developed to treat a specific form of congenital deafness linked to mutations in the OTOF (otoferlin) gene

Positive initial safety profile reported in all six patients treated so far

Data from Cohort 1, at the minimally effective dose, demonstrate early signs of hearing improvement in Patient 3, using a range of standard hearing tests

Data from Cohort 2, at a higher dose, are currently being gathered; Data Monitoring Committee expected by the end of H2 2025

GJB2-GT on track for

Sensorion Reports 2025 Half-Year Results, Provides Corporate Update and Announces Availability of Half-Year Report

Wed, 17 Sep 2025 01:30:00 -0400

Achieved expedited enrollment completion of first two Cohorts in Phase 1/2 Audiogene clinical trial evaluating SENS-501, the Company’s gene therapy candidate being developed to treat a specific form of congenital deafness linked to mutations in the OTOF (otoferlin) gene

Positive initial safety profile reported in all six patients treated so far

Data from Cohort 1, at the minimally effective dose, demonstrate early signs of hearing improvement in Patient 3, using a range of standard hearing tests

Data from Cohort 2, at a higher dose, are currently being gathered; Data Monitoring Committee expected by the end of H2 2025

GJB2-GT on track for

Sensorion Reports 2025 Half-Year Results, Provides Corporate Update and Announces Availability of Half-Year Report

Wed, 17 Sep 2025 01:30:00 -0400

Achieved expedited enrollment completion of first two Cohorts in Phase 1/2 Audiogene clinical trial evaluating SENS-501, the Company’s gene therapy candidate being developed to treat a specific form of congenital deafness linked to mutations in the OTOF (otoferlin) gene

Positive initial safety profile reported in all six patients treated so far

Data from Cohort 1, at the minimally effective dose, demonstrate early signs of hearing improvement in Patient 3, using a range of standard hearing tests

Data from Cohort 2, at a higher dose, are currently being gathered; Data Monitoring Committee expected by the end of H2 2025

GJB2-GT on track for

Sensorion Reports 2025 Half-Year Results, Provides Corporate Update and Announces Availability of Half-Year Report

Wed, 17 Sep 2025 01:30:00 -0400

Achieved expedited enrollment completion of first two Cohorts in Phase 1/2 Audiogene clinical trial evaluating SENS-501, the Company’s gene therapy candidate being developed to treat a specific form of congenital deafness linked to mutations in the OTOF (otoferlin) gene

Positive initial safety profile reported in all six patients treated so far

Data from Cohort 1, at the minimally effective dose, demonstrate early signs of hearing improvement in Patient 3, using a range of standard hearing tests

Data from Cohort 2, at a higher dose, are currently being gathered; Data Monitoring Committee expected by the end of H2 2025

GJB2-GT on track for

Sensorion Reports 2025 Half-Year Results, Provides Corporate Update and Announces Availability of Half-Year Report

Wed, 17 Sep 2025 01:30:00 -0400

Achieved expedited enrollment completion of first two Cohorts in Phase 1/2 Audiogene clinical trial evaluating SENS-501, the Company’s gene therapy candidate being developed to treat a specific form of congenital deafness linked to mutations in the OTOF (otoferlin) gene

Positive initial safety profile reported in all six patients treated so far

Data from Cohort 1, at the minimally effective dose, demonstrate early signs of hearing improvement in Patient 3, using a range of standard hearing tests

Data from Cohort 2, at a higher dose, are currently being gathered; Data Monitoring Committee expected by the end of H2 2025

GJB2-GT on track for

Sensorion Reports 2025 Half-Year Results, Provides Corporate Update and Announces Availability of Half-Year Report

Wed, 17 Sep 2025 01:30:00 -0400

Achieved expedited enrollment completion of first two Cohorts in Phase 1/2 Audiogene clinical trial evaluating SENS-501, the Company’s gene therapy candidate being developed to treat a specific form of congenital deafness linked to mutations in the OTOF (otoferlin) gene

Positive initial safety profile reported in all six patients treated so far

Data from Cohort 1, at the minimally effective dose, demonstrate early signs of hearing improvement in Patient 3, using a range of standard hearing tests

Data from Cohort 2, at a higher dose, are currently being gathered; Data Monitoring Committee expected by the end of H2 2025

GJB2-GT on track for

Sensorion Reports 2025 Half-Year Results, Provides Corporate Update and Announces Availability of Half-Year Report

Wed, 17 Sep 2025 01:30:00 -0400

Achieved expedited enrollment completion of first two Cohorts in Phase 1/2 Audiogene clinical trial evaluating SENS-501, the Company’s gene therapy candidate being developed to treat a specific form of congenital deafness linked to mutations in the OTOF (otoferlin) gene

Positive initial safety profile reported in all six patients treated so far

Data from Cohort 1, at the minimally effective dose, demonstrate early signs of hearing improvement in Patient 3, using a range of standard hearing tests

Data from Cohort 2, at a higher dose, are currently being gathered; Data Monitoring Committee expected by the end of H2 2025

GJB2-GT on track for

Sensorion Reports 2025 Half-Year Results, Provides Corporate Update and Announces Availability of Half-Year Report

Wed, 17 Sep 2025 01:30:00 -0400

Achieved expedited enrollment completion of first two Cohorts in Phase 1/2 Audiogene clinical trial evaluating SENS-501, the Company’s gene therapy candidate being developed to treat a specific form of congenital deafness linked to mutations in the OTOF (otoferlin) gene

Positive initial safety profile reported in all six patients treated so far

Data from Cohort 1, at the minimally effective dose, demonstrate early signs of hearing improvement in Patient 3, using a range of standard hearing tests

Data from Cohort 2, at a higher dose, are currently being gathered; Data Monitoring Committee expected by the end of H2 2025

GJB2-GT on track for

Sensorion Reports 2025 Half-Year Results, Provides Corporate Update and Announces Availability of Half-Year Report

Wed, 17 Sep 2025 01:30:00 -0400

Achieved expedited enrollment completion of first two Cohorts in Phase 1/2 Audiogene clinical trial evaluating SENS-501, the Company’s gene therapy candidate being developed to treat a specific form of congenital deafness linked to mutations in the OTOF (otoferlin) gene

Positive initial safety profile reported in all six patients treated so far

Data from Cohort 1, at the minimally effective dose, demonstrate early signs of hearing improvement in Patient 3, using a range of standard hearing tests

Data from Cohort 2, at a higher dose, are currently being gathered; Data Monitoring Committee expected by the end of H2 2025

GJB2-GT on track for

Sensorion Reports 2025 Half-Year Results, Provides Corporate Update and Announces Availability of Half-Year Report

Wed, 17 Sep 2025 01:30:00 -0400

Achieved expedited enrollment completion of first two Cohorts in Phase 1/2 Audiogene clinical trial evaluating SENS-501, the Company’s gene therapy candidate being developed to treat a specific form of congenital deafness linked to mutations in the OTOF (otoferlin) gene

Positive initial safety profile reported in all six patients treated so far

Data from Cohort 1, at the minimally effective dose, demonstrate early signs of hearing improvement in Patient 3, using a range of standard hearing tests

Data from Cohort 2, at a higher dose, are currently being gathered; Data Monitoring Committee expected by the end of H2 2025

GJB2-GT on track for

Sensorion Reports 2025 Half-Year Results, Provides Corporate Update and Announces Availability of Half-Year Report

Wed, 17 Sep 2025 01:30:00 -0400

Achieved expedited enrollment completion of first two Cohorts in Phase 1/2 Audiogene clinical trial evaluating SENS-501, the Company’s gene therapy candidate being developed to treat a specific form of congenital deafness linked to mutations in the OTOF (otoferlin) gene

Positive initial safety profile reported in all six patients treated so far

Data from Cohort 1, at the minimally effective dose, demonstrate early signs of hearing improvement in Patient 3, using a range of standard hearing tests

Data from Cohort 2, at a higher dose, are currently being gathered; Data Monitoring Committee expected by the end of H2 2025

GJB2-GT on track for

Sensorion Strengthens Leadership Team with Appointment of Amit Munshi as Chairman of the Board and Independent Director

Wed, 02 Apr 2025 01:30:00 -0400

MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced the appointment of Amit Munshi, as Sensorion’s independent director and Chairman of the Board, effective April 1, 2025. Mr. Munshi succeeds Mr. John Furey who stepped down as an Independent Board Member. Mr. Munshi is then appointed Chairman of the Board, replacing Khalil Barrage who served as the Company’s interim Chairman since March 31, 2023. Mr. Barrage will continue to serve as a director on Sensorion’s Board.
This

Sensorion Strengthens Leadership Team with Appointment of Amit Munshi as Chairman of the Board and Independent Director

Wed, 02 Apr 2025 01:30:00 -0400

MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced the appointment of Amit Munshi, as Sensorion’s independent director and Chairman of the Board, effective April 1, 2025. Mr. Munshi succeeds Mr. John Furey who stepped down as an Independent Board Member. Mr. Munshi is then appointed Chairman of the Board, replacing Khalil Barrage who served as the Company’s interim Chairman since March 31, 2023. Mr. Barrage will continue to serve as a director on Sensorion’s Board.
This

Sensorion Strengthens Leadership Team with Appointment of Amit Munshi as Chairman of the Board and Independent Director

Wed, 02 Apr 2025 01:30:00 -0400

MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced the appointment of Amit Munshi, as Sensorion’s independent director and Chairman of the Board, effective April 1, 2025. Mr. Munshi succeeds Mr. John Furey who stepped down as an Independent Board Member. Mr. Munshi is then appointed Chairman of the Board, replacing Khalil Barrage who served as the Company’s interim Chairman since March 31, 2023. Mr. Barrage will continue to serve as a director on Sensorion’s Board.
This

Sensorion Strengthens Leadership Team with Appointment of Amit Munshi as Chairman of the Board and Independent Director

Wed, 02 Apr 2025 01:30:00 -0400

MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced the appointment of Amit Munshi, as Sensorion’s independent director and Chairman of the Board, effective April 1, 2025. Mr. Munshi succeeds Mr. John Furey who stepped down as an Independent Board Member. Mr. Munshi is then appointed Chairman of the Board, replacing Khalil Barrage who served as the Company’s interim Chairman since March 31, 2023. Mr. Barrage will continue to serve as a director on Sensorion’s Board.
This

Sensorion Strengthens Leadership Team with Appointment of Amit Munshi as Chairman of the Board and Independent Director

Wed, 02 Apr 2025 01:30:00 -0400

MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced the appointment of Amit Munshi, as Sensorion’s independent director and Chairman of the Board, effective April 1, 2025. Mr. Munshi succeeds Mr. John Furey who stepped down as an Independent Board Member. Mr. Munshi is then appointed Chairman of the Board, replacing Khalil Barrage who served as the Company’s interim Chairman since March 31, 2023. Mr. Barrage will continue to serve as a director on Sensorion’s Board.
This

Sensorion Strengthens Leadership Team with Appointment of Amit Munshi as Chairman of the Board and Independent Director

Wed, 02 Apr 2025 01:30:00 -0400

MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced the appointment of Amit Munshi, as Sensorion’s independent director and Chairman of the Board, effective April 1, 2025. Mr. Munshi succeeds Mr. John Furey who stepped down as an Independent Board Member. Mr. Munshi is then appointed Chairman of the Board, replacing Khalil Barrage who served as the Company’s interim Chairman since March 31, 2023. Mr. Barrage will continue to serve as a director on Sensorion’s Board.
This

Sensorion Strengthens Leadership Team with Appointment of Amit Munshi as Chairman of the Board and Independent Director

Wed, 02 Apr 2025 01:30:00 -0400

MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced the appointment of Amit Munshi, as Sensorion’s independent director and Chairman of the Board, effective April 1, 2025. Mr. Munshi succeeds Mr. John Furey who stepped down as an Independent Board Member. Mr. Munshi is then appointed Chairman of the Board, replacing Khalil Barrage who served as the Company’s interim Chairman since March 31, 2023. Mr. Barrage will continue to serve as a director on Sensorion’s Board.
This

Sensorion Strengthens Leadership Team with Appointment of Amit Munshi as Chairman of the Board and Independent Director

Wed, 02 Apr 2025 01:30:00 -0400

MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced the appointment of Amit Munshi, as Sensorion’s independent director and Chairman of the Board, effective April 1, 2025. Mr. Munshi succeeds Mr. John Furey who stepped down as an Independent Board Member. Mr. Munshi is then appointed Chairman of the Board, replacing Khalil Barrage who served as the Company’s interim Chairman since March 31, 2023. Mr. Barrage will continue to serve as a director on Sensorion’s Board.
This

Sensorion Strengthens Leadership Team with Appointment of Amit Munshi as Chairman of the Board and Independent Director

Wed, 02 Apr 2025 01:30:00 -0400

MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced the appointment of Amit Munshi, as Sensorion’s independent director and Chairman of the Board, effective April 1, 2025. Mr. Munshi succeeds Mr. John Furey who stepped down as an Independent Board Member. Mr. Munshi is then appointed Chairman of the Board, replacing Khalil Barrage who served as the Company’s interim Chairman since March 31, 2023. Mr. Barrage will continue to serve as a director on Sensorion’s Board.
This